On-line Table 1: Failure to attribute primary outcome[a]

	PRET-1		PRET-2		PRET	
	Platinum (*n* = 125)	Hydrogel (*n* = 125)	Platinum (*n* = 97)	Hydrogel (*n* =100)	Platinum (*n* = 222)	Hydrogel (*n* = 225)
Missing outcome	1 (0.8%)	3 (2.4%)	1 (1.0%)	4 (4.0%)	2 (0.9%)	7 (3.1%)
Unrelated mortality	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Lost to follow-up	1 (0.8%)	1 (0.8%)	1 (1.0%)	3 (3.0%)	2 (0.9%)	4 (1.8%)
Consent withdrawn	0 (0.0%)	1 (0.8%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	2 (0.9%)

[a] Distribution of patients in which no primary outcome was attributed. Data are numbers.

On-line Table 2: Primary outcome in patients in PRET with an unruptured aneurysm[a]

	PRET-1		PRET-2		PRET	
	Platinum (*n* = 87)	Hydrogel (*n* = 88)	Platinum (*n* = 94)	Hydrogel (*n* = 91)	Platinum (*n* = 181)	Hydrogel (*n* = 179)
Primary outcome	35 (40.2%)	42 (47.7%)	45 (47.9%)	38 (41.8%)	80 (44.2%)	80 (44.7%)
Major recurrence	21 (24.1%)	29 (33.0%)	31 (33.0%)	25 (27.5%)	52 (28.7%)	54 (30.2%)
Retreatment	6 (6.9%)	9 (10.2%)	10 (10.6%)	5 (5.5%)	16 (8.8%)	14 (7.8%)
Initial treatment failure	2 (2.3%)	0 (0.0%)	0 (0.0%)	4 (4.4%)	2 (1.1%)	4 (2.2%)
SAH	1 (1.1%)	0 (0.0%)	1 (1.1%)	1 (1.1%)	2 (1.1%)	1 (0.6%)
Mass effect	0 (0.0%)	1 (1.1%)	3 (3.2%)	0 (0.0%)	3 (1.7%)	1 (0.6%)
Related mortality	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
Related morbidity	2 (2.3%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	2 (1.1%)	1 (0.6%)
Last observation carried forward[b]	2 (2.3%)	2 (2.3%)	0 (0.0%)	3 (3.3%)	2 (1.1%)	5 (2.8%)

[a] Data are numbers.

[b] Residual aneurysm at initial treatment and no angiographic follow-up.

On-line Table 3: Primary outcome in patients in PRET with an internal carotid aneurysm[a]

	PRET-1		PRET-2		PRET	
	Platinum (*n* = 58)	Hydrogel (*n* = 66)	Platinum (*n* = 43)	Hydrogel (*n* = 40)	Platinum (*n* = 101)	Hydrogel (*n* = 106)
Primary outcome	24 (41.4%)	32 (48.5%)	20 (46.5%)	18 (45.0%)	44 (43.6%)	50 (47.2%)
Major recurrence	16 (27.6%)	17 (25.8%)	13 (30.2%)	10 (25.0%)	29 (28.7%)	27 (25.5%)
Retreatment	5 (8.6%)	11 (16.7%)	6 (14.0%)	5 (12.5%)	11 (10.9%)	16 (15.1%)
Initial treatment failure	1 (1.7%)	0 (0.0%)	0 (0.0%)	1 (2.5%)	1 (1.0%)	1 (0.9%)
SAH	0 (0.0%)	1 (1.5%)	1 (2.3%)	1 (2.5%)	1 (1.0%)	2 (1.9%)
Mass effect	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Related mortality	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Related morbidity	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Last observation carried forward[b]	2 (3.4%)	2 (3.0%)	0 (0.0%)	1 (2.5%)	2 (2.0%)	3 (2.8%)

[a] Data are numbers.

[b] Residual aneurysm at initial treatment and no angiographic follow-up.

On-line Table 4: Primary outcome in patients in PRET with stent-assisted coiling[a]

	PRET-1		PRET-2		PRET	
	Platinum (*n* = 25)	Hydrogel (*n* = 28)	Platinum (*n* = 32)	Hydrogel (*n* = 34)	Platinum (*n* = 57)	Hydrogel (*n* = 62)
Primary outcome	12 (48.0%)	20 (71.4%)	14 (43.8%)	9 (26.5%)	26 (45.6%)	29 (46.8%)
Major recurrence	6 (24.0%)	15 (53.6%)	9 (28.1%)	5 (14.7%)	15 (26.3%)	20 (32.3%)
Retreatment	2 (8.0%)	2 (7.1%)	3 (9.4%)	2 (5.9%)	5 (8.8%)	4 (6.5%)
Initial treatment failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SAH	1 (4.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Mass effect	0 (0.0%)	1 (3.6%)	2 (6.3%)	0 (0.0%)	2 (3.5%)	1 (1.6%)
Related mortality	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Related morbidity	2 (8.0%)	1 (3.6%)	0 (0.0%)	1 (2.9%)	2 (3.5%)	2 (3.2%)
Last observation carried forward[b]	1 (4.0%)	1 (3.6%)	0 (0.0%)	1 (2.9%)	1 (1.8%)	2 (3.2%)

[a] Data are numbers.

[b] Residual aneurysm at initial treatment and no angiographic follow-up.

On-line Table 5: Sensitivity analyses

Primary Outcome	PRET-1			PRET-2			PRET		
	Platinum	Hydrogel	OR, 95% CI, *P* Value	Platinum	Hydrogel	OR, 95% CI, *P* Value	Platinum	Hydrogel	OR, 95% CI, *P* Value
Patients with angiographic outcome only ($n = 426$)	51 (42.5%)	61 (51.7%)	1.448 (0.868–2.414) .156	47 (49.0%)	37 (40.2%)	0.701 (0.394–1.250) .229	98 (45.4%)	98 (46.7%)	1.054 (0.720–1.542) .788
Missing outcome attributed to primary outcome not met (good) ($n = 444$)	55 (44.4%)	63 (51.2%)	1.336 (0.811–2.203) .255	47 (48.5%)	40 (40.4%)	0.721 (0.410–1.270) .257	102 (45.9%)	103 (46.4%)	1.018 (0.701–1.479) .924
Missing outcome attributed to primary outcome met (poor) ($n = 444$)	56 (44.8%)	66 (53.7%)	1.427 (0.865–2.352) .164	48 (49.5%)	44 (44.4%)	0.817 (0.466–1.432) .480	104 (46.8%)	110 (49.5%)	1.114 (0.768–1.617) .569
Including patients withdrawn before intervention ($n = 447$)	56 (44.8%)	68 (54.4%)	1.470 (0.893–2.419) .130	48 (49.5%)	45 (45.0%)	0.835 (0.477–1.462) .529	104 (46.8%)	113 (50.2%)	1.145 (0.790–1.659) .475

On-line Table 6: Sensitivity analyses on the primary outcome when hydrogel target length was met[a]

Primary Outcome	PRET-1	PRET-2	PRET	
	OR, 95% CI, *P* Value	OR, 95% CI, *P* Value	OR, 95% CI, *P* Value	Effect Modification (Interaction) (*P* Value)
Primary outcome ($n = 404$)	1.415 (0.834–2.401) .199	0.642 (0.354–1.163) .144	0.993 (0.671–1.471) .973	.052
Patients with angiographic outcome only ($n = 395$)	1.468 (0.858–2.511) .161	0.581 (0.317–1.065) .079	0.973 (0.653–1.449) .893	.025
Missing outcome attributed to primary outcome not met (good) ($n = 413$)	1.349 (0.799–2.277) .262	0.608 (0.337–1.096) .098	0.943 (0.640–1.392) .769	.047
Missing outcome attributed to primary outcome met (poor) ($n = 413$)	1.468 (0.869–2.479) .151	0.707 (0.395–1.265) .243	1.054 (0.716–1.553) .789	.067
Including patients withdrawn before intervention ($n = 413$)	1.468 (0.869–2.479) .151	0.707 (0.395–1.265) .243	1.054 (0.716–1.553) .789	.067

[a] Sensitivity analysis when patients treated with hydrogel were restricted to those in whom the target hydrogel length was met (>two-thirds of total length).

On-line Table 7: Mortality[a]

	PRET-1		PRET-2		PRET	
	Platinum ($n = 125$)	Hydrogel ($n = 123$)	Platinum ($n = 97$)	Hydrogel ($n = 99$)	Platinum ($n = 222$)	Hydrogel ($n = 222$)
Total	3 (2.4%)	10 (8.1%)	0 (0.0%)	3 (3.0%)	3 (1.4%)	13 (5.9%)
Related to SAH at presentation	0 (0.0%)	2 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.9%)
Delayed, related to initial treatment	1 (0.8%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
Related to SAH during follow-up	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.5%)	1 (0.5%)
Related to retreatment	0 (0.0%)	2 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.9%)
Unrelated	1 (0.8%)	5 (4.1%)	0 (0.0%)	2 (2.0%)	1 (0.5%)	7 (3.2%)

[a] Overall mortality, recorded at any time point during the trial. Data are numbers.

On-line Table 8: Unrelated mortality details[a]

ID	PRET Type	Treatment Group	Age (yr)	Aneurysm Location	mRS at Last Follow-Up	Days After Intervention	Underlying Cause of Death
15	PRET-2	Hydrogel coils	74	Other posterior	0	508	Heart attack
38	PRET-1	Hydrogel coils	61	Other posterior	0	169	Cancer recurrence
97	PRET-1	Hydrogel coils	68	Basilar	0	718	Complications associated with pneumonia following hip fracture
242	PRET-1	Hydrogel coils	69	Internal carotid	0	241	Death from sepsis following knee replacement
248	PRET-1	Hydrogel coils	78	Internal carotid	0	957	Complications from pneumonia following broken leg
280	PRET-1	Platinum coils	75	Middle cerebral	0	410	Polyvisceral, septic etiology (community pneumonia)
356	PRET-1	Hydrogel coils	67	Internal carotid	3	362	Metastatic breast cancer
417	PRET-2	Hydrogel coils	80	Internal carotid	0	622	Per death certificate, lymphoma stated as cause of death

Note:—ID indicates identification.

[a] Cause of death and patient and aneurysm characteristics when mortality was not related to the aneurysm or its treatment.